{"id":5999,"date":"2026-07-22T09:22:23","date_gmt":"2026-07-22T09:22:23","guid":{"rendered":"https:\/\/pharmanomos.ch\/effective-capa-from-the-root-cause-to-verifying-effectiveness\/"},"modified":"2026-07-22T09:24:27","modified_gmt":"2026-07-22T09:24:27","slug":"effective-capa-from-the-root-cause-to-verifying-effectiveness","status":"publish","type":"post","link":"https:\/\/pharmanomos.ch\/en\/effective-capa-from-the-root-cause-to-verifying-effectiveness\/","title":{"rendered":"Effective CAPA: From the Root Cause to Verifying Effectiveness"},"content":{"rendered":"\n

Introduction<\/h2>\n\n

In the pharmaceutical and life sciences sectors, an effective CAPA links five elements: nonconformity, risk, cause, actions, and evidence of effectiveness. If any one of these elements is weak, the process risks becoming nothing more than a collection of administrative tasks: updating an SOP, retraining staff, sending a reminder to the supplier, and closing the case. <\/p>\n\n

The goal, however, is to understand why the event occurred and to take action on the system that was supposed to prevent or detect it. This approach makes CAPA a concrete part of the quality system<\/strong><\/a>, not merely a matter of fulfilling documentation requirements. <\/p>\n\t\t\t\t

\n\t\t\t\t
\n\t\t\t\t\t\t
\n\t\t\t\t\t\t\tArticle Contents<\/strong>\t\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t\t
\n\t\t\t\t\t\t
  1. Introduction<\/a>
  2. CAPA within the Swiss Regulatory Framework<\/a>
  3. Correction, corrective action, preventive action, and improvement<\/a>
  4. How to Properly Describe a Nonconformity<\/a>
  5. Assess Criticality, Impact, and Urgency<\/a>
  6. How to Conduct a Root Cause Analysis<\/a>
  7. Define SMART actions, responsibilities, and deadlines<\/a>
  8. Practically verify effectiveness<\/a>
  9. Complete CAPA Example: Temperature Deviation<\/a>
  10. When a CAPA Can Be Closed<\/a>
  11. Errors That Make CAPA Ineffective<\/a>
  12. Operational Checklist for Effective CAPA<\/a>
  13. Conclusion<\/a><\/ol>\t\t\t\t\t<\/div>\n\t\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\n
    <\/div>\n\n

    CAPA within the Swiss Regulatory Framework<\/h2>\n\n

    For organizations subject to Swiss pharmaceutical legislation, the obligations depend on the activities carried out and the scope of the authorization. TheOrdinance on the Authorization of Medicines<\/strong><\/a> stipulates that manufacturing must comply with the GMP rules set forth in the relevant annexes. For wholesale distribution, Swissmedic refers to the applicable GDP requirements through Article 15 and Annex 4 of the ordinance. <\/p>\n\n

    During GMP and GDP inspections, Swissmedic may examine, among other aspects, deviation management, documentation, training, monitoring of storage conditions, supplier qualification, complaints, outsourced activities, and self-inspections. Re-inspections may also verify the corrective actions required during a previous visit. <\/p>\n\n

    The PIC\/S GMP Guide PE 009-17<\/strong><\/a> requires an appropriate level of root cause analysis, corrective or preventive actions consistent with the findings of the investigation, and monitoring of their effectiveness. It also specifies that attributing the event to human error must be justified, after first verifying that no process, procedural, or system issues have been overlooked. <\/p>\n\n

    Tools such as the 5 Whys, the Ishikawa diagram, and the SMART framework are best practices<\/strong>, not specific legal requirements. Also, ISO 9001:2015<\/strong><\/a> is a voluntary standard, unless it becomes applicable due to a company\u2019s choice, certification, contract, or other provision. As of July 21, 2026, the 2015 edition is still current; ISO plans to release a new edition in the coming months. <\/p>\n\n

    <\/div>\n\n

    Correction, corrective action, preventive action, and improvement<\/h2>\n\n
    Concept<\/th>Purpose<\/th>Example<\/th><\/tr><\/thead>
    Correction<\/strong><\/td>Resolve or address the nonconformity that has already been identified<\/td>Quarantine products affected by temperature fluctuations<\/td><\/tr>
    Corrective Action<\/strong><\/td>Eliminate the cause of the nonconformity to prevent it from recurring<\/td>Modify the alarm system that failed to promptly notify of the excursion<\/td><\/tr>
    Preventive Action<\/strong><\/td>Eliminate the cause of a potential nonconformity<\/td>Apply the same improvement to other refrigerators with a similar configuration<\/td><\/tr>
    Improvement<\/strong><\/td>Improve performance, reliability, or ease of use, even without a nonconformity<\/td>Digitizing the SOP Approval Workflow<\/td><\/tr><\/tbody><\/table><\/figure>\n\n

    Replacing an outdated copy of an SOP is a correction. Revising the process for distributing, collecting, and checking copies, on the other hand, is a corrective action. <\/p>\n\n

    Under ISO 9001:2015, prevention is integrated into risk-based thinking and is no longer a separate clause. In the pharmaceutical sector, however, the term CAPA typically continues to encompass both corrective and preventive actions. <\/p>\n\n

    <\/div>\n\n

    How to Properly Describe a Nonconformity<\/h2>\n\n

    An effective description must include verifiable facts, not hypotheses about the cause. According to the ISO\/IAF guidance, a well-documented nonconformity includes the unmet requirement, objective evidence, and a clear statement of the deviation. <\/p>\n\n

    A practical structure is:<\/p>\n\n

    \n

    On [date and time]<\/strong>, during the process or at the location [where]<\/strong>, [measurable fact]<\/strong> was observed regarding [products, lots, documents, or records involved]<\/strong>, in violation of [requirement, SOP, specification, or authorized condition]<\/strong>, as demonstrated by [evidence]<\/strong>.<\/p>\n<\/blockquote>\n\n

    Example \u2013 Temperature Deviation<\/strong><\/p>\n\n

    \n

    On July 14, 2026, the L-03 data logger in refrigerator F-02 recorded a maximum temperature of 11.8 \u00b0C for 47 minutes, compared to the expected range of 2\u20138 \u00b0C. Batches A and B were present in the refrigerator. The products were placed in quarantine pending a documented impact assessment. <\/p>\n<\/blockquote>\n\n

    The description should not jump to the conclusion that \u201cthe operator left the door open\u201d until the hypothesis has been verified.<\/p>\n\n

    <\/div>\n\n

    Assess Criticality, Impact, and Urgency<\/h2>\n\n

    The initial assessment is used to determine containment measures, the scope of the investigation, responsibilities, and the timeline for handling the situation. It may consider: <\/p>\n\n